Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19231354 | OPHTHALMIC COMPOSITIONS FOR TREATMENT OF OCULAR SURFACE DAMAGE AND SYMPTOMS OF DRYNESS | June 2025 | March 2026 | Abandon | 9 | 1 | 0 | No | No |
| 18949801 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS | November 2024 | January 2026 | Abandon | 14 | 1 | 1 | No | No |
| 18614993 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | March 2024 | March 2025 | Abandon | 12 | 2 | 0 | No | No |
| 18496137 | GLP-1R MODULATING COMPOUNDS | October 2023 | October 2025 | Allow | 24 | 1 | 1 | No | No |
| 18238091 | PHARMACEUTICAL COMPOSITION | August 2023 | January 2026 | Abandon | 28 | 5 | 1 | Yes | No |
| 18137893 | NOVEL QUINOLIN-2-YL NITRONES USEFUL FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES | April 2023 | November 2025 | Abandon | 30 | 2 | 1 | No | Yes |
| 18090647 | PHARMACEUTICAL COMPOSITION | December 2022 | January 2025 | Abandon | 24 | 2 | 1 | Yes | No |
| 18077844 | SALVINORIN COMPOSITIONS | December 2022 | September 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17937758 | METHODS AND COMPOSITIONS FOR TREATING CARDIOMYOPATHY AND HEART FAILURE | October 2022 | January 2026 | Abandon | 39 | 4 | 1 | Yes | No |
| 17954557 | PHARMACEUTICAL COMPOSITIONS CONTAINING PARACETAMOL DERIVATIVES AND USE THEREOF | September 2022 | June 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17931456 | CRYSTALLINE FORM OF TLR8 AGONIST | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17903216 | CHEMICAL COMPOUNDS | September 2022 | October 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17802908 | METHODS AND MATERIALS FOR DIAGNOSIS AND TREATMENT OF NEURONAL DISORDER | August 2022 | March 2026 | Allow | 42 | 1 | 0 | No | No |
| 17892620 | METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 35-64 YEARS | August 2022 | February 2025 | Abandon | 30 | 2 | 0 | No | No |
| 17795929 | COMPOUNDS AND USES THEREOF | July 2022 | January 2026 | Allow | 42 | 1 | 1 | No | No |
| 17874984 | NOVEL COMPOSITIONS INCLUDING CANNABIS AND AVOCADO/SOYBEAN UNSAPONIFIABLES AND METHODS OF USE | July 2022 | March 2026 | Allow | 44 | 2 | 0 | No | No |
| 17857991 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | July 2022 | February 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17853035 | METHOD FOR ALLEVIATING ARTHRITIS USING EPIDERMAL GROWTH FACTOR | June 2022 | November 2025 | Abandon | 41 | 4 | 0 | No | No |
| 17835051 | 18-MC FOR TREATING OBESITY | June 2022 | June 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17832566 | BVP8 PROTEIN FOR KILLING TETRANYCHID MITES AND USE THEREOF | June 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17831276 | USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE | June 2022 | June 2024 | Abandon | 24 | 2 | 0 | Yes | No |
| 17737218 | RAS INHIBITORS | May 2022 | September 2024 | Allow | 29 | 1 | 1 | No | No |
| 17770924 | Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug | April 2022 | November 2025 | Allow | 43 | 0 | 0 | No | No |
| 17691260 | CONTACT LENS TREATING SOLUTION | March 2022 | January 2026 | Allow | 46 | 3 | 1 | No | Yes |
| 17620095 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | December 2021 | March 2026 | Abandon | 51 | 2 | 0 | No | No |
| 17552792 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17538821 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | November 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17614530 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17595796 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | November 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17612889 | TREATMENT OF OCULAR DISEASE | November 2021 | January 2026 | Abandon | 50 | 2 | 0 | Yes | No |
| 17610787 | TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS | November 2021 | February 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17605975 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS | October 2021 | March 2026 | Allow | 52 | 2 | 1 | No | No |
| 17600587 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | September 2021 | July 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17600178 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | September 2021 | July 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17441082 | PESTICIDALLY ACTIVE AZOLE AMIDE COMPOUNDS | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17458031 | SYNTHESIS OF POZIOTINIB DERIVATIVE | August 2021 | May 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17429968 | SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALT | August 2021 | May 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17430025 | CANCER TREATMENT | August 2021 | March 2026 | Allow | 55 | 1 | 0 | No | No |
| 17429301 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PKR-ASSOCIATED DISEASES | August 2021 | July 2025 | Allow | 47 | 1 | 0 | No | No |
| 17428396 | METHODS AND COMPOSITIONS FOR MODULATING BLOOD-BRAIN BARRIER | August 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17415279 | USE OF OLANZAPINE FOR TREATMENT OF PARP-INHIBITOR-INDUCED NAUSEA | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17413139 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | June 2021 | September 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17296073 | COMPOSITION COMPRISING A CHOLINE SALT OF A FATTY ACID AND ITS USE AS A FUNGICIDE | May 2021 | August 2025 | Allow | 51 | 3 | 0 | Yes | Yes |
| 17325934 | HETEROCYCLIC COMPOUNDS | May 2021 | June 2025 | Allow | 49 | 1 | 1 | No | No |
| 17292663 | CRYSTALLINE FORMS OF A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND AND USE THEREOF AS P2X3 MODULATOR | May 2021 | June 2025 | Allow | 49 | 3 | 0 | No | No |
| 17291547 | FLAVONOID DELIVERY SYSTEM | May 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17056947 | THERAPEUTIC OR PREVENTING AGENT FOR MULTIPLE SCLEROSIS INCLUDING INDOLE COMPOUND | April 2021 | July 2025 | Allow | 55 | 2 | 0 | No | No |
| 17287901 | Next Generation Synthetic Transcription Factors | April 2021 | July 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17286799 | TREATMENT OF NEUROLOGICAL DISEASE | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17281395 | INDOLE AHR INHIBITORS AND USES THEREOF | March 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17278585 | OPHTHALMIC COMPOSITIONS FOR TREATMENT OF OCULAR SURFACE DAMAGE AND SYMPTOMS OF DRYNESS | March 2021 | February 2026 | Abandon | 59 | 4 | 0 | No | No |
| 17276972 | QUINOLINE DERIVATIVE USED FOR TREATING SMALL CELL LUNG CANCER | March 2021 | September 2025 | Abandon | 54 | 4 | 0 | No | No |
| 17276920 | TLR8 AGONIST | March 2021 | April 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17276375 | PROPHYLACTIC AGENT FOR SPONTANEOUS CANCERS | March 2021 | March 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17187877 | LIQUID FORMULATION OF BIPHENYL-CONTAINING COMPOUND AND APPLICATION THEREOF | February 2021 | July 2025 | Allow | 52 | 4 | 0 | Yes | No |
| 17272129 | MACROCYCLIC CHELATES AND USES THEREOF | February 2021 | September 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17173069 | NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASES | February 2021 | February 2024 | Allow | 36 | 3 | 0 | No | No |
| 17265883 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | February 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17265982 | TISSUE TRANSGLUTAMINASE MODULATORS FOR MEDICINAL USE | February 2021 | November 2025 | Abandon | 58 | 3 | 1 | No | No |
| 17146327 | FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 | January 2021 | January 2024 | Allow | 37 | 1 | 1 | No | No |
| 16972368 | METHOD OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE-2,4-DIONE | December 2020 | March 2026 | Allow | 60 | 5 | 0 | No | Yes |
| 17045392 | TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVES | October 2020 | November 2024 | Abandon | 49 | 0 | 1 | No | No |
| 16987092 | ACRIDINIUM ESTER-CONTAINING COMPOUNDS AND METHODS OF USING THE SAME FOR CHEMILUMINESCENCE-BASED ONE-COLOR SEQUENCING | August 2020 | March 2025 | Allow | 55 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ADLAM, CHANTAL PETA-GAYE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ADLAM, CHANTAL PETA-GAYE works in Art Unit 1622 and has examined 39 patent applications in our dataset. With an allowance rate of 43.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner ADLAM, CHANTAL PETA-GAYE's allowance rate of 43.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ADLAM, CHANTAL PETA-GAYE receive 1.72 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ADLAM, CHANTAL PETA-GAYE is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +39.5% benefit to allowance rate for applications examined by ADLAM, CHANTAL PETA-GAYE. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.7% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.